NO20025784L - Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme - Google Patents
Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter sammeInfo
- Publication number
- NO20025784L NO20025784L NO20025784A NO20025784A NO20025784L NO 20025784 L NO20025784 L NO 20025784L NO 20025784 A NO20025784 A NO 20025784A NO 20025784 A NO20025784 A NO 20025784A NO 20025784 L NO20025784 L NO 20025784L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical formulation
- substance
- hmg
- chemical synthesis
- coa reductase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000855 fermentation Methods 0.000 abstract 2
- 230000004151 fermentation Effects 0.000 abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000894007 species Species 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 241000187643 Amycolatopsis Species 0.000 abstract 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 1
- 241000235395 Mucor Species 0.000 abstract 1
- 241000187654 Nocardia Species 0.000 abstract 1
- 241000228143 Penicillium Species 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/591,322 US6531507B1 (en) | 2000-06-09 | 2000-06-09 | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| PCT/IB2000/000773 WO2001093860A1 (fr) | 2000-06-09 | 2000-06-09 | Composition stabilisee pharmaceutiquement efficace et preparation pharmaceutique comprenant cette composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20025784D0 NO20025784D0 (no) | 2002-12-02 |
| NO20025784L true NO20025784L (no) | 2002-12-02 |
Family
ID=26318615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025784A NO20025784L (no) | 2000-06-09 | 2002-12-02 | Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6531507B1 (fr) |
| EP (1) | EP1292293B1 (fr) |
| JP (1) | JP2004501121A (fr) |
| AT (1) | ATE260101T1 (fr) |
| AU (2) | AU4943400A (fr) |
| BG (1) | BG107360A (fr) |
| CA (1) | CA2412326A1 (fr) |
| CZ (1) | CZ20023826A3 (fr) |
| DE (1) | DE60008608T2 (fr) |
| ES (1) | ES2215050T3 (fr) |
| HR (1) | HRP20020950A2 (fr) |
| HU (1) | HUP0301325A3 (fr) |
| NO (1) | NO20025784L (fr) |
| PL (1) | PL362764A1 (fr) |
| RU (1) | RU2246943C2 (fr) |
| SI (1) | SI1292293T1 (fr) |
| SK (1) | SK16982002A3 (fr) |
| UA (1) | UA70410C2 (fr) |
| WO (1) | WO2001093860A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110196039A9 (en) * | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US6806290B2 (en) * | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| EP1345903A1 (fr) * | 2000-12-21 | 2003-09-24 | Ciba SC Holding AG | Formes cristallines de sodium de cerivastatine |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| EP1404303A4 (fr) * | 2001-06-21 | 2006-03-15 | Andrx Pharmaceuticals Inc | Compositions pharmaceutiques stables a base de pravastatine |
| US20040180087A1 (en) * | 2001-06-21 | 2004-09-16 | Boyong Li | Stable controlled release pharmaceutical compositions containing pravastatin |
| WO2003013607A1 (fr) * | 2001-08-07 | 2003-02-20 | Galephar M/F | Composition pharmaceutique orale contenant une combinaison de fenofibrate et d'un inhibiteur de hmg-coa reductase |
| US20030153617A1 (en) * | 2001-12-18 | 2003-08-14 | Dalen Frans Van | Simvastatin dosage forms |
| CA2385529A1 (fr) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Formulations posologiques stables contenant de l'atorvastatin calcium |
| ATE409476T1 (de) * | 2002-06-13 | 2008-10-15 | Novartis Pharma Gmbh | Calciumsalze von statinen aus indol |
| SI21302A (sl) * | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| US20060029668A1 (en) * | 2002-10-24 | 2006-02-09 | Ron Eyal S | Sustained release L-arginine formulations and methods of manufacture and use |
| CA2503284A1 (fr) * | 2002-10-24 | 2004-05-06 | Enos Pharmaceuticals, Inc. | Preparations de l-arginine a liberation prolongee et procedes de fabrication et d'utilisation de celles-ci |
| US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
| KR20050088190A (ko) * | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| EP1675619A4 (fr) * | 2003-09-29 | 2010-10-06 | Palmetto Pharmaceuticals Llc | Formulations de l'arginine a liberation prolongee, procedes de fabrication et utilisations |
| US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
| EP1737449A1 (fr) * | 2004-03-01 | 2007-01-03 | LEK Pharmaceuticals D.D. | Composition pharmaceutique |
| AU2004317570B2 (en) | 2004-03-17 | 2011-01-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| US7491263B2 (en) * | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
| KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| NZ552390A (en) * | 2004-08-06 | 2010-01-29 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| BRPI0514189A (pt) * | 2004-08-06 | 2008-06-03 | Transform Pharmaceuticals Inc | composições farmacêuticas de estatina e métodos de tratamento relacionados |
| AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| CA2595651A1 (fr) * | 2005-01-24 | 2006-08-03 | Enos Pharmaceuticals, Inc. | Methodes de traitement de diverses conditions par administration de l-arginine a liberation prolongee |
| US20080182887A1 (en) * | 2005-02-22 | 2008-07-31 | Sun Pharmaceutical Industries Limited | Stable Oral Pharmaceutical Composition |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| JP4813841B2 (ja) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | プラバスタチンナトリウムの製造方法 |
| WO2007016757A1 (fr) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Compositions pharmaceutiques a liberation prolongee, stabilisees, comprenant un inhibiteur de l'hmg-coa reductase |
| WO2007020079A2 (fr) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Comprimes de simvastatine a desintegration orale |
| EP1818049A3 (fr) * | 2006-02-10 | 2008-11-19 | LifeCycle Pharma A/S | Atorvastatin stabilisée |
| CA2642195A1 (fr) * | 2006-02-24 | 2007-09-07 | Teva Pharmaceutical Industries Ltd. | Compositions pharmaceutiques de fluvastatine sodique |
| DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
| WO2013072770A2 (fr) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride |
| KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES493726A0 (es) * | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
| US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| CA2150372C (fr) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Composition orale stable de ci-981 et procede de preparation |
| US5798375A (en) | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| DE69634054T2 (de) * | 1995-07-17 | 2005-12-08 | Warner-Lambert Co. | Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin) |
| DE122011000014I1 (de) * | 1995-12-22 | 2011-11-03 | Kowa Co | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium. |
| SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
-
2000
- 2000-06-09 JP JP2002501433A patent/JP2004501121A/ja active Pending
- 2000-06-09 CA CA002412326A patent/CA2412326A1/fr not_active Abandoned
- 2000-06-09 EP EP00931486A patent/EP1292293B1/fr not_active Revoked
- 2000-06-09 CZ CZ20023826A patent/CZ20023826A3/cs unknown
- 2000-06-09 PL PL00362764A patent/PL362764A1/xx not_active Application Discontinuation
- 2000-06-09 SI SI200030324T patent/SI1292293T1/xx unknown
- 2000-06-09 AT AT00931486T patent/ATE260101T1/de active
- 2000-06-09 WO PCT/IB2000/000773 patent/WO2001093860A1/fr not_active Ceased
- 2000-06-09 AU AU4943400A patent/AU4943400A/xx active Pending
- 2000-06-09 HR HRP20020950 patent/HRP20020950A2/hr not_active Application Discontinuation
- 2000-06-09 US US09/591,322 patent/US6531507B1/en not_active Expired - Fee Related
- 2000-06-09 RU RU2002134764/15A patent/RU2246943C2/ru not_active IP Right Cessation
- 2000-06-09 HU HU0301325A patent/HUP0301325A3/hu unknown
- 2000-06-09 DE DE60008608T patent/DE60008608T2/de not_active Expired - Lifetime
- 2000-06-09 AU AU2000249434A patent/AU2000249434B2/en not_active Ceased
- 2000-06-09 ES ES00931486T patent/ES2215050T3/es not_active Expired - Lifetime
- 2000-06-09 SK SK1698-2002A patent/SK16982002A3/sk not_active Application Discontinuation
- 2000-09-06 UA UA2002119464A patent/UA70410C2/uk unknown
-
2002
- 2002-12-02 NO NO20025784A patent/NO20025784L/no not_active Application Discontinuation
- 2002-12-06 BG BG107360A patent/BG107360A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1292293T1 (en) | 2004-06-30 |
| HUP0301325A2 (hu) | 2003-11-28 |
| BG107360A (bg) | 2003-11-28 |
| SK16982002A3 (sk) | 2003-04-01 |
| AU2000249434B2 (en) | 2006-02-02 |
| EP1292293A1 (fr) | 2003-03-19 |
| DE60008608D1 (de) | 2004-04-01 |
| CZ20023826A3 (cs) | 2003-04-16 |
| CA2412326A1 (fr) | 2001-12-13 |
| US6531507B1 (en) | 2003-03-11 |
| AU4943400A (en) | 2001-12-17 |
| PL362764A1 (en) | 2004-11-02 |
| DE60008608T2 (de) | 2004-12-30 |
| EP1292293B1 (fr) | 2004-02-25 |
| JP2004501121A (ja) | 2004-01-15 |
| HUP0301325A3 (en) | 2004-03-01 |
| HRP20020950A2 (en) | 2004-12-31 |
| RU2246943C2 (ru) | 2005-02-27 |
| NO20025784D0 (no) | 2002-12-02 |
| UA70410C2 (en) | 2004-10-15 |
| ES2215050T3 (es) | 2004-10-01 |
| WO2001093860A1 (fr) | 2001-12-13 |
| ATE260101T1 (de) | 2004-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20025784D0 (no) | Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme | |
| NZ511260A (en) | Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor | |
| IL187261A0 (en) | Crystals of the sodium salt of pravastatin | |
| IS2113B (is) | Ný sölt HMG-CoA redúktasatálma | |
| ATE284396T1 (de) | Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer | |
| IL141785A0 (en) | A pharmaceutical composition containing an ap2 inhibitor | |
| DE69909508D1 (de) | Verfahren zur herstellung von simvastatin und deren analogen | |
| ATE418979T2 (de) | Stabilisiertes arzneimittel und arzneizubereitung | |
| US7230120B2 (en) | Amorphous HMG-CoA reductase inhibitors of desired particle size | |
| YU88602A (sh) | Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže | |
| CO5611117A2 (es) | Combinacion de compuestos organicos | |
| TH52206A (th) | สารที่รวมเข้าด้วยกันของ สแททิน-คาร์บอกซิแอลคิลอีเธอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |